Predictive factors on the receipt and completion of adjuvant chemotherapy in a mixed sociodemographic cohort of patients.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 6137-6137
Author(s):  
Blase N. Polite ◽  
David M Smith ◽  
Toni Cipriano

6137 Background: African Americans are more likely to die from breast, colon and lung cancer compared to whites. They are also less likely to receive and complete recommended therapy. The reasons for this are unknown. Methods: Breast, colon, and lung cancer patients eligible for adjuvant chemotherapy (stage IB-III breast, stage IIB-III colon, and Stage IB, II lung) and who received surgery at 2 urban medical centers, were approached between 2008 and 2010 and completed a self-administered survey focusing on sociodemographic factors, including social support, anxiety, depression, co-morbidities, trust and God Locus of Control (e.g., Whatever happens to my cancer is God’s will). These variables were related to receipt and completion of chemotherapy. 191 patients were approached, 161 consented and 30 refused (16%); out of the 161, 23 were deemed ineligible because of previous cancers, non-curative stage or receipt of chemotherapy in the neoadjuvant setting. Results: Final sample consisted of 138 pts. Median age: 54; sex:81% F; Race/Ethnicity:47% AA, 38% white, 9% Hispanic, 6% Asian/PI; Cancer Type: 73% Breast, 21% Colon, 6% Lung. Compared to whites, AA were more likely to have incomes<20K (35% vs. 10%, p=.0002), have any comorbidities (80% vs. 57%, p=0.006), and have high levels of God Locus of Control (56% vs 27%, p=0.003). There were no differences by race in chemotherapy receipt (89% vs. 88%) or relative dose intensity (RDI) of chemo>=85% (58% vs. 67%). No factor in our model predicted chemotherapy receipt or RDI at a significant level. Pts with high God Locus of Control were somewhat more likely to start chemotherapy (OR 1.7, p=0.25) but were less likely to complete therapy (OR 0.55, p=0.19). The magnitude of these relationships held after controlling for age, race, comorbidities, cancer type, functional status, and social support. Conclusions: In a mixed sociodemographic cohort of patients, receipt and completion of adjuvant chemotherapy was similar by measured sociodemographic variables. Only high God Locus of Control was suggestive of being less likely to complete chemotherapy. Further attention and research on the role of religious beliefs in the cancer decision making process is warranted.

Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1812
Author(s):  
Philip Baum ◽  
Samantha Taber ◽  
Stella Erdmann ◽  
Thomas Muley ◽  
Mark Kriegsmann ◽  
...  

The current pT3N0 category represents a heterogeneous subgroup involving tumor size, separate tumor nodes in one lobe, and locoregional growth pattern. We aim to validate outcomes according to the eighth edition of the TNM staging classification. A total of 281 patients who had undergone curative lung cancer surgery staged with TNM-7 in two German centers were retrospectively analyzed. The subtypes tumor size >7 cm and multiple nodules were grouped as T3a, and the subtypes parietal pleura invasion and mixed were grouped as T3b. We stratified survival by subtype and investigated the relative benefit of adjuvant chemotherapy according to subtype. The 5-year overall survival (OS) rates differed between the different subtypes tumor diameter >7 cm (71.5%), multiple nodules in one lobe (71.0%) (grouped as T3a), parietal pleura invasion (59.%), and mixed subtype (5-year OS 50.3%) (grouped as T3b), respectively. The cohort as a whole did not gain significant OS benefit from adjuvant chemotherapy. In contrast, adjuvant chemotherapy significantly improved OS in the T3b subgroup (logrank p = 0.03). This multicenter cohort analysis of pT3N0 patients identifies a new prognostic mixed subtype. Tumors >7 cm should not be moved to pT4. Patients with T3b tumors have significantly worse survival than patients with T3a tumors.


2021 ◽  
Vol 39 (28_suppl) ◽  
pp. 79-79
Author(s):  
Jenny Jing Xiang ◽  
Alicia Roy ◽  
Christine Summers ◽  
Monica Delvy ◽  
Jessica Lee O'Donovan ◽  
...  

79 Background: Patient-trial matching is a critical step in clinical research recruitment that requires extensive review of clinical data and trial requirements. Prescreening, defined as identifying potentially eligible patients using select eligibility criteria, may streamline the process and increase study enrollment. We describe the real-world experience of implementing a standardized, universal clinical research prescreening protocol within a VA cancer center and its impact on research enrollment. Methods: An IRB approved prescreening protocol was implemented at the VACT Cancer Center in March 2017. All patients with a suspected or confirmed diagnosis of cancer are identified through tumor boards, oncology consults, and clinic lists. Research coordinators perform chart review and manually enter patient demographics, cancer type and stage, and treatment history into a REDCap (Research Electronic Data Capture) database. All clinical trials and their eligibility criteria are also entered into REDCap and updated regularly. REDCap generates real time lists of potential research studies for each patient based on his/her recorded data. The primary oncologist is alerted to a patient’s potential eligibility prior to upcoming clinic visits and thus can plan to discuss clinical research enrollment as appropriate. Results: From March 2017 to December 2020, a total of 2548 unique patients were prescreened into REDCAP. The mean age was 71.5 years, 97.5% were male, and 15.5% were African American. 32.57 % patients had genitourinary cancer, 17.15% had lung cancer, and 46.15% were undergoing malignancy workup. 1412 patients were potentially eligible after prescreening and 556 patients were ultimately enrolled in studies. The number of patients enrolled on therapeutic clinical trials increased after the implementation of the prescreening protocol (35 in 2017, 64 in 2018, 78 in 2019, and 55 in 2020 despite the COVID19 pandemic). Biorepository study enrollment increased from 8 in 2019 to 15 in 2020. The prescreening protocol also enabled 200 patients to be enrolled onto a lung nodule liquid biopsy study from 2017 to 2019. Our prescreening process captured 98.57% of lung cancer patients entered into the cancer registry during the same time period. Conclusions: Universal prescreening streamlined research recruitment operations and was associated with yearly increases in clinical research enrollment at a VA cancer center. Our protocol identified most new lung cancer patients, suggesting that, at least for this malignancy, potential study patients were not missed. The protocol was integral in our program becoming the top accruing VA site for NCI’s National Clinical Trial Network (NCTN) studies since 2019.


2021 ◽  
Vol Volume 13 ◽  
pp. 2319-2327
Author(s):  
Adriana Hofman ◽  
Natalia Zajdel ◽  
Jakub Klekowski ◽  
Mariusz Chabowski

Sign in / Sign up

Export Citation Format

Share Document